866-997-4948(US-Canada Toll Free)

Prostate Cancer - UK Drug Forecasts and Treatment Analysis to 2020

Published By :

GlobalData

Published Date : Nov 2010

Category :

Cancer

No. of Pages : 202 Pages


GlobalData's pharmaceutical report, Prostate Cancer UK Drug Forecasts and Treatment Analysis to 2020 is an essential source of information and analysis on the UK prostate cancer therapeutics market. The report provides comprehensive information on prostate cancer, highlighting the treatment guidelines. It identifies and analyzes the key trends shaping and driving the UK prostate cancer therapeutics market, and analyzes the treatment usage patterns. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. The report provides valuable insights into the pipeline products within the global prostate cancer sector. It quantifies the unmet need in the UK prostate cancer therapeutics market, highlighting the opportunity for future players. 

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalDatas team of industry experts. 

Scope

The scope of the report includes: 

  • An overview of prostate cancer which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
  • Annualized UK prostate cancer therapeutics market revenue, annual cost of therapy and treatment usage patterns data (for hormone therapy and hormone resistant or refractory therapy) from 2001 to 2009, forecast for 11 years to 2020. 
  • Insightful review of the key industry drivers, restraints and challenges and predicted impact of key events. 
  • Competitor assessment including drug launch analysis and drug sales forecasts.
  • Product profiles covering efficiency, safety, clinical study details, annual cost, regulatory approvals, LCM (Life Cycle Management) activities and drug sales forecast.
  • Analysis of unmet need in the market and target product profiles including opportunity for target products. 
  • Technology trends analytic framework to assess the strength of the pipeline. 
  • Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include EGFR inhibitors, VEGF inhibitors, tyrosine kinase inhibitor, angiogenesis inhibitors and others.
  • An overview of the most promising drugs including clinical study details, efficacy, safety, collaboration agreements, marketing rights and launch analysis.
  • Analysis of the current and future market competition in the UK Prostate Cancer therapeutics market. Company profiles including business description, financial overview and SWOT analysis. Key future market players covered include Sanofi-aventis, Pfizer, Inc., AstraZeneca PLC, Bristol-Myers Squibb, Medivation, Takeda Pharmaceuticals and Dendreon Corporation.
  • Analysis of licensing agreements during 2004-2010 in the prostate cancer therapeutics market. Merger and Acquisition (M&A analysis) which includes M&A deals by size and geography.
  • Strategic assessment of the market through market impact analysis, future market scenario and company analysis.
  • Direct quotes from key opinion leaders (KOL) or physicians in the prostate cancer therapeutics market in the UK.
Reasons to buy

The report will enhance your decision making capability. It will allow you to:

  • Develop business strategies and perform superior market quantification analysis by 
  • Understanding the trends shaping and driving the UK prostate cancer therapeutics market. 
  • Understanding the treatment preferences of physicians for each disease state and across treatment flow.
  • Accessing market sizing forecasts and quantified growth opportunities in the UK prostate cancer therapeutics market up to 2020.
  • Quantifying the patient population in the UK to better design product pricing and launch plans.
  • Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape by
  • Performing benchmarking analysis and growth opportunities against currently marketed products.
  • Identifying market entry points based on safety, efficacy, and pricing parameters. 
  • Assessing competitiveness of products in the market by understanding the strengths and weaknesses of current competition. 
  • Develop and design your in-licensing and out-licensing strategies by 
  • Taking a comprehensive look at the disease pipeline and identifying the most promising paradigm-shifting products.
  • Assessing the strength of pipeline based on first-in-class, me-too and generic products and their lifecycle management.
  • Track drug sales in the UK prostate cancer therapeutics market from 2001 to 2020.
  • Identify the emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. 
  • Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for consolidation, investments and strategic partnerships.
  • Whats the next big thing in the UK prostate cancer therapeutics market landscape? Identify, understand and capitalize.
Table Of Content

1 Table of contents
1.1 List of Tables
1.2 List of Figures

2 Disease Overview
2.1 Overview
2.1.1 TNM (Tumor, Nodes, Metastasis) Staging System
2.1.2 Jewett-Whitmore system
2.2 Epidemiology
2.3 Etiology
2.4 Symptoms
2.4.1 Localized or Locally Advanced Prostate Cancer
2.4.2 Metastatic Prostate Cancer
2.5 Diagnosis
2.5.1 Digital Rectal Examination
2.5.2 Prostate Specific Antigen Test
2.5.3 Transrectal Ultrasound
2.5.4 Prostate Biopsy
2.6 Pathology
2.6.1 Grading
2.7 Treatment
2.7.1 Watchful Waiting
2.7.2 Radiation therapy
2.7.3 Surgery
2.7.4 Hormone therapy
2.7.5 Chemotherapy Options
2.7.6 Other Treatments Being Studied
2.8 Treatment Guidelines

3 Market Characterization
3.1 The UK
3.1.1 Market Size
3.1.2 Drivers and Barriers
3.1.3 Impact on the Market
3.1.4 Forecasts
3.1.5 Drug Sales
3.1.6 Pricing and Reimbursements

4 Competitor Assessment
4.1 Strategic Competitor Assessment
4.1.1 Overview
4.1.2 Benchmarking
4.1.3 Current Competitor Assessment
4.2 Launch Analysis and Sales Forecasts
4.3 Product Profiles
4.3.1 Taxotere (docetaxel)
4.3.2 Casodex (Bicalutamide)
4.3.3 Zoladex (Goserelin)
4.3.4 Prostap (leuprolide acetate)
4.3.5 Firmagon (degarelix)
4.3.6 Novantrone (Mitoxantrone hydrochloride)
4.3.7 Emcyt (estramustine)
4.3.8 Trelstar (triptorelin)
4.3.9 Eulexin
4.3.10 Delestrogen
4.3.11 Gynodiol
4.3.12 Estrace tablet
4.3.13 Tace
4.3.14 Nilandrone
4.3.15 Premarin
4.3.16 Sales Forecast for Trelstar, Decapeptyl, Gonapeptyl, Flutamide, Estradiol

5 Pipeline Assessment
5.1 Overview
5.2 Pipeline Analysis by Phase of Development
5.3 Pipeline by Mechanism of Action
5.4 Strategic Pipeline Assessment
5.4.1 Technology Trends Analytical Framework
5.5 Trends in Prostate Cancer Pipeline
5.5.1 More Clarity on the Origin of Prostate Cancer Will Help in Identifying Novel Targets for Prostate Cancer Drugs
5.5.2 Molecules with Novel Mechanism of Action Strengthening Prostate Cancer Pipeline
5.5.3 Failure of Key Molecules to Achieve Positive Results in Phase III Development
5.6 Partners in Research and Development
5.6.1 Licensing Agreements by Phase of Development
5.6.2 Licensing Agreements by Geography
5.6.3 Licensing Agreements: Technology Licensing Agreements in Prostate Cancer
5.7 Most Promising Drugs' Profiles
5.7.1 Provenge (sipuleucel-T)
5.7.2 Jevtana (cabazitaxel)
5.7.3 Aflibercept (VEGF Trap)
5.7.4 Ipilimumab
5.7.5 Abiraterone Acetate (CB7630)
5.7.6 Zibotentan (ZD4054)
5.7.7 Sprycel (dasatinib)
5.7.8 MDV3100
5.8 Prostate Cancer Pipeline – Pre-clinical Phase
5.9 Prostate Cancer Pipeline – Phase I
5.10 Prostate Cancer Pipeline – Phase II
5.11 Prostate Cancer Pipeline – Phase III
5.12 Key Takeaway

6 Unmet Need and Target Product Profile
6.1 Unmet Need
6.1.1 Hormone-independent Metastatic Prostate Cancer Therapy
6.1.2 Hormone-dependent Metastatic Prostate Cancer Therapy
6.2 Opportunity for Target Product
6.3 Target Product Profile
6.3.1 Ideal Characteristics
6.3.2 Target Product Description
6.4 Key Takeaway

7 Strategic Assessment
7.1 Key Events Impacting the Future Market
7.2 Market Impact Analysis
7.3 Future Market Scenario
7.4 Company Analysis
7.4.1 Market Leadership
7.4.2 Future Players in the Market
7.5 Key Takeaway

8 Company Profiles
8.1 Sanofi-aventis
8.1.1 Business Description
8.1.2 Financial Overview
8.1.3 SWOT Analysis
8.1.4 Oncology Focus
8.2 Pfizer Inc.
8.2.1 Business Description
8.2.2 Financial Overview
8.2.3 SWOT Analysis
8.2.4 Oncology Focus
8.3 AstraZeneca
8.3.1 Business Description
8.3.2 Financial Overview
8.3.3 SWOT Analysis
8.3.4 Oncology Focus
8.4 Bristol-Myers Squibb
8.4.1 Business Description
8.4.2 Financial Overview
8.4.3 SWOT Analysis
8.5 Medivation
8.5.1 Business Description
8.5.2 SWOT Analysis
8.5.3 Oncology Focus
8.6 Takeda Pharmaceuticals
8.6.1 Business Description
8.6.2 SWOT Analysis
8.7 Dendreon Corporation
8.7.1 Business Description
8.7.2 SWOT Analysis
8.8 Johnson and Johnson
8.8.1 Business Description
8.8.2 SWOT Analysis
8.8.3 Oncology Focus
8.9 Auron Healthcare GmbH
8.9.1 Business Description
8.10 Oncogenex Pharmaceuticals, Inc.
8.10.1 Business Description
8.11 Agennix AG
8.11.1 Business Description
8.12 GTx, Inc.
8.12.1 Business Description
8.13 GlaxoSmithKline plc.
8.13.1 Business Description
8.13.2 Financial Overview
8.13.3 SWOT Analysis
8.13.4 Oncology Focus

9 M&A Analysis
9.1 Key Highlights
9.2 Key Deals' Analysis
9.2.1 Johnson & Johnson Acquires Cougar Biotechnology
9.2.2 Endo Pharmaceuticals Acquires Indevus Pharmaceuticals
9.2.3 Tolmar Holding Acquires QLT USA from QLT
9.2.4 Biomarin Pharmaceutical to Acquire Lead therapeutics
9.2.5 Isis Pharmaceuticals Reacquires Rights to Cancer Drug from Eli Lilly & Co.
9.2.6 Quest PharmaTech Acquires Late-stage Immunotherapeutic Antibody Pipeline from Paladin Labs
9.2.7 VaxOnco Acquires Rights to Onyvax-P Cell Vaccine From Onyvax
9.2.8 GPC Biotech Merges with Agennix
9.2.9 Eli Lilly Acquires ImClone
9.2.10 BBM Holdings Acquires YM BioSciences
9.2.11 Sagent Pharmaceuticals Acquires Injectable Generic Drug Applications of Spectrum Pharmaceuticals
9.3 M&A Deals by Geography
9.4 M&A Deals by Deal Size

10 Expert Opinion
10.1 UK
11 Appendix
11.1 Market Definitions
11.2 Abbreviations
11.3 Research Methodology
11.3.1 Coverage
11.3.2 Secondary Research
11.3.3 Forecasting
11.3.4 Primary Research
11.3.5 Expert Panel validation
11.3.6 Contact Us
11.3.7 Disclaimer
11.3.8 Sources

List of Table


Table 1: Prostate Cancer Therapeutics Market, Global, Staging of the Prostate Cancer, 2010 11
Table 2: Prostate Cancer, Global, Age Related PSA Levels (ng/ml), 2010 14
Table 3: Prostate Cancer Therapeutics Market, UK, Sales Value ($m), 2001-2009 20
Table 4: Prostate Cancer Therapeutics Market, UK, Annual Cost of Therapy ($), 2001-2009 21
Table 5: Prostate Cancer Therapeutics Market, UK, Patient Volume (000s), 2001-2009 22
Table 6: Prostate Cancer Therapeutics Market, UK, Treatment Usage Patterns (000s), 2001-2009 24
Table 7: Prostate Cancer Therapeutics Market, UK, Sales Value ($m), 2009-2020 28
Table 8: Prostate Cancer Therapeutics Market, UK, Annual Cost of Therapy ($), 2009-2020 29
Table 9: Prostate Cancer Therapeutics Market, UK, Patient Volume (000s), 2009-2020 30
Table 10: Prostate Cancer Therapeutics Market, UK, Treatment Usage Patterns (000s), 2009-2020 31
Table 11: Prostate Cancer Therapeutics Market, UK, Hormone-refractory Prostate Cancer Drug Sales ($m), 2001-2010 35
Table 12: Prostate Cancer Therapeutics Market, UK, Hormone-refractory Prostate Cancer Drug Sales ($m), 2011-2020 35
Table 13: Prostate Cancer Therapeutics Market, UK, Hormone-dependent Prostate Cancer Drug Sales ($m), 2001-2010 37
Table 14: Prostate Cancer Therapeutics Market, UK, Hormone-dependent Prostate Cancer Drug Sales ($m), 2011-2020 37
Table 15: Prostate Cancer, Global, Clinical Endpoints for Benchmarking, 2010 40
Table 16: Prostate Cancer, Global, Chemotherapy, Safety Profile of Standard Care Treatment, 2010 41
Table 17: Prostate Cancer, Global, Hormone Therapy, Safety Profile of Standard Care Treatment, 2010 42
Table 18: Prostate Cancer, UK, Benchmarking Major Marketed Products, 2010 46
Table 19: Prostate Cancer, Global, Casodex, Incidence of Adverse Effects, 2010 51
Table 20: Prostate Cancer, Global, Licensing Agreements, 2009-2010 82
Table 21: Prostate Cancer, Global, Technology Licensing Agreements Description, 2010 84
Table 22: Prostate Cancer, Global, Most Promising Drugs Under Clinical Development, 2010 85
Table 23: Prostate Cancer, Global, Pre-clinical Phase Pipeline, August 2010 104
Table 24: Prostate Cancer, Global, Phase I Pipeline, August 2010 106
Table 25: Prostate Cancer, Global, Phase II Pipeline, August 2010 108
Table 26: Prostate Cancer, Global, Phase III Pipeline, August 2010 115
Table 27: Prostate Cancer, Global, Characteristics of Ideal Drug Which Satisfies the Unmet Needs of the Market, 2010 122
Table 28: Prostate Cancer, Global, Description of Ideal Drug Which Satisfies the Unmet Needs of the Market, 2010 123
Table 29: Prostate Cancer, Johnson & Johnson, Oncology Late Stage Pipeline by Indication, 2010 176
Table 30: Prostate Cancer, Global, Auron Healthcare, Key Pipeline Products, 2010 177
Table 31: Prostate Cancer, Global, M&A Deals by Geography, 2010 188

List of Chart


Figure 1: Prostate Cancer Therapeutics Market, Global, Treatment Guidelines, 2010 19
Figure 2: Prostate Cancer Therapeutics Market, UK, Sales Value ($m), 2001-2009 20
Figure 3: Prostate Cancer Therapeutics Market, UK, Annual Cost of Therapy ($), 2001-2009 21
Figure 4: Prostate Cancer Therapeutics Market, UK, Patient Volume (000s), 2001-2009 22
Figure 5: Prostate Cancer Therapeutics Market, UK, Treatment Usage Patterns (000s), 2001-2009 23
Figure 6: Prostate Cancer Therapeutics Market, The UK, Market Drivers and Restraints, 2009 26
Figure 7: Prostate Cancer Therapeutics Market, The UK, Historical Events Impact on the Market, 2010 27
Figure 8: Prostate Cancer Therapeutics Market, UK, Sales Value ($m), 2009-2020 28
Figure 9: Prostate Cancer Therapeutics Market, UK, Annual Cost of Therapy ($), 2009-2020 29
Figure 10: Prostate Cancer Therapeutics Market, UK, Patient Volume (000s), 2009-2020 30
Figure 11: Prostate Cancer Therapeutics Market, UK, Treatment Usage Patterns (000s), 2009-2020 31
Figure 12: Prostate Cancer Therapeutics Market, The UK, Future Market Drivers and Restraints, 2009-2020 33
Figure 13: Prostate Cancer Therapeutics Market, UK, Hormone-refractory Prostate Cancer Drug Sales ($m), 2001-2020 34
Figure 14: Prostate Cancer Therapeutics Market, UK, Hormone-dependent Prostate Cancer Drug Sales ($m), 2001-2020 36
Figure 15: Prostate Cancer, Global, Strategic Competitor Assessment of Major Marketed Drugs, Chemotherapy Drugs, 2010 43
Figure 16: Prostate Cancer, Global, Strategic Competitor Assessment of Major Marketed Drugs, Hormone Therapy Drugs, 2010 44
Figure 17: Prostate Cancer Therapeutics Market, UK, Sales Forecast by Therapies, 2001-2020 45
Figure 18: Prostate Cancer, Global, Taxotere, Chemical Structure 47
Figure 19: Prostate Cancer, Global, Taxotere, LCM Activities, 2004-2010 48
Figure 20: Prostate Cancer, UK, Taxotere, Sales ($m), 2004-2020 49
Figure 21: Prostate Cancer, Global, Casodex, Chemical Structure 50
Figure 22: Prostate Cancer, Global, Casodex, LCM Activities, 2004-2010 53
Figure 23: Prostate Cancer, UK, Casodex, Sales ($m), 2001-2020 54
Figure 24: Prostate Cancer, Global, Zoladex, Chemical Structure 55
Figure 25: Prostate Cancer, UK, Zoladex, Sales Forecast ($m), 2001-2020 56
Figure 26: Prostate Cancer, UK, Leuprolide (Prostap), Sales Forecast ($m), 2001-2020 58
Figure 27: Prostate Cancer, Global, Firmagon, Chemical Structure 58
Figure 28: Prostate Cancer, UK, Firmagon, Sales Forecast ($m), 2008-2020 60
Figure 29: Prostate Cancer, Global, Novatrone, Chemical Structure 61
Figure 30: Prostate Cancer, UK, Mitoxantrone, Sales Forecast ($m), 2001-2020 62
Figure 31: Prostate Cancer, Global, Emcyt, Chemical Structure 63
Figure 32: Prostate Cancer, UK, Estramustine, Sales Forecast ($m), 2001-2020 64
Figure 33: Prostate Cancer, Global, Trelstar, Chemical Structure 64
Figure 34: Prostate Cancer, Global, Eulexin, Chemical Structure 66
Figure 35: Prostate Cancer, Global, Delestrogen, Chemical Structure 68
Figure 36: Prostate Cancer, Global, Gynodiol, Chemical Structure 69
Figure 37: Prostate Cancer, Global, Estrace, Chemical Structure 70
Figure 38: Prostate Cancer, Global, Tace, Chemical Structure 71
Figure 39: Prostate Cancer, Global, Nilandrone, Chemical Structure 72
Figure 40: Prostate Cancer, Global, Premarin, Chemical Structure 73
Figure 41: Prostate Cancer, UK, Combined sales of Trelstar, Decapeptyl, Gonapeptyl, Flutamide, Estradiol, Sales Forecast ($m), 2001-2020 74
Figure 42: Prostate Cancer, Global, Clinical Trials by Therapy, 2010 75
Figure 43: Prostate Cancer, Global, Clinical Trials by Phase of Development, 2010 76
Figure 44: Prostate Cancer, Global, Pipeline by Mechanism of Action, 2010 77
Figure 45: Prostate Cancer, Global, Technology Trends Analytic Framework of Pipeline Drugs, 2010 78
Figure 46: Prostate Cancer, Global, Technology Trends Description of Pipeline Drugs, 2010 79
Figure 47: Prostate Cancer, Global, Licensing Agreements by Phase of Development, 2009-2010 80
Figure 48: Prostate Cancer, Global, Licensing Agreements by Geography, 2010 83
Figure 49: Prostate Cancer, UK, Provenge, Sales Forecast ($m), 2009-2020 88
Figure 50: Prostate Cancer, UK, Jevtana, Sales Forecast ($m), 2001-2020 89
Figure 51: Prostate Cancer, Global, Aflibercept, Chemical Structure 90
Figure 52: Prostate Cancer, UK, Aflibercept, Sales Forecast ($m), 2009-2020 92
Figure 53: Prostate Cancer, UK, Ipilimumab , Sales Forecast ($m), 2009-2020 94
Figure 54: Prostate Cancer, Global, Abiraterone, Chemical Structure 95
Figure 55: Prostate Cancer, UK, Abiraterone, Sales Forecast ($m), 2009-2020 97
Figure 56: Prostate Cancer, Global, Zibotentan, Chemical Structure 97
Figure 57: Prostate Cancer, UK, Zibotentan , Sales Forecast ($m), 2009-2020 99
Figure 58: Prostate Cancer, UK, Sprycel , Sales Forecast ($m), 2009-2020 100
Figure 59: Prostate Cancer, Global, MDV3100, Chemical Structure 101
Figure 60: Prostate Cancer, UK, MDV3100 , Sales Forecast ($m), 2009-2020 103
Figure 61: Prostate Cancer, Global, Median Overall Survival for Hormone-independent Metastatic Prostate Cancer Patients, 2010 117
Figure 62: Prostate Cancer, Global, Median Overall Survival for Hormone-dependent Metastatic Prostate Cancer Patients, 2010 118
Figure 63: Prostate Cancer, Global, Hormone-dependent Metastatic Prostate Cancer Patients Achieving Castrate Level Testosterone Level in 28-30 Days (%), 2010 118
Figure 64: Prostate Cancer, UK, Prostate Cancer, Opportunity and Unmet Need, 2010 119
Figure 65: Prostate Cancer, UK, Hormone-independent Metastatic Prostate Cancer, Opportunity and Unmet Need, 2010 121
Figure 66: Prostate Cancer, UK, Hormone-dependent Metastatic Prostate Cancer, Opportunity and Unmet Need, 2010 122
Figure 67: Prostate Cancer, Global, Key Events Impacting the Future Market 124
Figure 68: Prostate Cancer, UK, Implications for Future Market Competition, 2010 125
Figure 69: Prostate Cancer, Global, Future Players in the Market, 2010 127
Figure 70:Prostate Cancer, Sanofi-aventis, Major Pharmaceutical Drugs 2010 128
Figure 71: Prostate Cancer, Sanofi-aventis Pasteur, Diseases Under Each Vaccination Area 2010 129
Figure 72: Prostate Cancer, Global, Sanofi-aventis, SWOT Analysis, 2010 130
Figure 73: Prostate Cancer, Sanofi-aventis, Therapeutic Segment Share of Pipeline 2010 135
Figure 74: Prostate Cancer, Global, Pfizer, SWOT Analysis 2010 137
Figure 75: Prostate Cancer, Pfizer, Distribution of Pipeline by Phase, 2010 143
Figure 76: Prostate Cancer, Pfizer, Therapeutic Segment Share of Pipeline 2010 144
Figure 77: Prostate Cancer, Astrazeneca, Key Products Portfolio 2010 145
Figure 78: Prostate Cancer, Global, AstraZeneca, SWOT Analysis 2010 146
Figure 79: Prostate Cancer, AstraZeneca, Oncology Products for Different Cancers 2010 150
Figure 80: Prostate Cancer, AstraZeneca, Distribution of Pipeline, by Phase, 2010 151
Figure 81: Prostate Cancer, AstraZeneca, Therapeutic Segment Share of Pipeline 2010 151
Figure 82: Prostate Cancer, Bristol-Myers Squibb, Key Products Portfolio 2010 152
Figure 83: Prostate Cancer, Global, Company Bristol-Myers Squibb, SWOT Analysis, 2010 153
Figure 84: Prostate Cancer, Bristol-Myers Squibb, Distribution of Pipeline by Phase, 2010 159
Figure 85: Prostate Cancer, Bristol-Myers Squibb, Therapeutic Segment Share of Pipeline 2010 159
Figure 86: Prostate Cancer, Global, Medivation, SWOT Analysis 2010 160
Figure 87: Prostate Cancer, Global, Takeda Pahrmaceuticals, SWOT Analysis 2010 164
Figure 88: Prostate Cancer, Global, Dendreon Corporation, SWOT Analysis 2010 166
Figure 89: Prostate Cancer, Global, Johnson and Johnson, SWOT Analysis 2010 170
Figure 90: Prostate Cancer, Johnson & Johnson, Late Stage Pipeline by Therapy Area, 2010 177
Figure 91: Prostate Cancer, Global, GlaxoSmithKline, SWOT Analysis 2010 180
Figure 92: Prostate Cancer, GlaxoSmithKline, Distribution of Pipeline by Phase, 2010 186
Figure 93: Prostate Cancer, GlaxoSmithKline, Therapeutic Segment Share of Pipeline 2010 187
Figure 94: Prostate Cancer, Global, M&A Deals by Geography of Target Companies, 2010 192
Figure 95: Prostate Cancer, Global, M&A Deals by Deal Size, 2010 192
Figure 96: Prostate Cancer, UK, Key Data Inputs from KOL Interviews, July 2010 193
Figure 97: GlobalData Market Forecasting Model 199

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *